TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05832411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoangle
Description: there is additional information presented to endoscopists:（1）the virtual stomach model monitoring；（2）time;（3）scoring.
Study: NCT06626776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral sinus lift with using allograft and collagen membrane
Description: sinus floor elevation with placing allograft and collagen membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral sinus lift with using exteneded platelet rich fibrin
Description: sinus floor elevation with placing eprf
Study: NCT05886023

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High nitrate vegetables
Description: Vegetable burger containing high nitrate vegetables

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low nitrate vegetables
Description: Vegetable burger containing to low nitrate vegetables
Study: NCT06401512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-determination (GSD) follow-up approach by primary care nurses.
Description: The GSD counseling program consists of four scheduled consultations with a nurse and a digital platform with tools to help people better manage their health. The consultations will be facilitated by using reflection sheets to stimulate written reflection in the context of GSD.
Study: NCT06435221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT05831202

Intervention type: DEVICE
Group type: OTHER
Intervention: The SEAL™ Saccular Endovascular Aneurysm Lattice System
Description: All adult subjects between 22 and 80 years of age and presenting with an unruptured or ruptured saccular Wide Neck intracranial aneurysm with less or equal to 19 mm in its equatorial width (2mm-19mm range) that in the opinion of the Principal Investigator (PI) requires treatment and suitable candidate for intrasaccular flow diversion treatment, who meet all eligibility criteria, will be considered for study enrollment.
Study: NCT06075901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Flossing
Description: Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Cuff
Description: Inflatable device that exerts an external pressure above a muscle or joint of the extremities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training Protocol
Description: The lower limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 4 weeks, with 3 training sessions per week, with a day break between sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Protocol
Description: The lower limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 4 weeks, with 3 training sessions per week, with a day break between sessions.
Study: NCT06485531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pranamaya
Description: Pranamaya

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pursed Lips Breathing
Description: Pursed Lips Breathing
Study: NCT04927663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-YJH08
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-YJH08
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-YJH08
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional Tumor Biopsy
Description: Optional procedure to obtain tumor tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional Tumor Biopsy
Description: Optional procedure to obtain tumor tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional Tumor Biopsy
Description: Optional procedure to obtain tumor tissue
Study: NCT05313230

Intervention type: OTHER
Intervention: CITRASATE SLED
Description: Applying of CITRASATE SLED
Study: NCT05394844

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6
Description: Dexcom G6 CGM device
Study: NCT04641286

Intervention type: OTHER
Intervention: Body motion categorisation
Description: All patients will receive passive motion categorisation monitoring
Study: NCT05553132

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier
Description: Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip. There are not enough cartilage cells to fill the defect so cartilage cells need to be mixed with MSCs. MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair. MSCs can be found in bone marrow and in the fatty tissues (i.e., area under the skin of the belly or breast) of patients. Fibrin glue is a product made from the naturally occurring compounds in blood which cause clotting. This glue hardens into a gel-like substance into which cells such as cartilage cells (chondrons) and AMSCs can be placed.
Study: NCT05361512

Intervention type: DEVICE
Intervention: Tsui test
Description: The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.

Intervention type: DEVICE
Intervention: epidural waveform analysis
Description: A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
Study: NCT04221958

Intervention type: DEVICE
Intervention: Electrocardiogram
Description: An electrocardiogram measures the electrical activity of the heartbeat. This intervention will be used on healthy adult volunteers whom are part of the staff at the institution.
Study: NCT05827666

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy milk alternative beverage
Description: Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy milk alternative beverage
Description: Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy milk alternative beverage
Description: Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.
Study: NCT05276219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: A diuretic (iv furosemide) strategy for decongestion in acute heart failure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide and isosorbide dinitrate
Description: Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
Study: NCT06627270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Participants will receive metronidazole (500 mg t.i.d. x 10 days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Mouth rinse chlorhexidine (10 ml t.i.d. x 10 days)
Study: NCT05373173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-assessment + In-person assessment
Description: All consented families will complete an initial home-based tele-assessment visit via Zoom that includes the TAP-Preschool and a brief symptom-focused developmental interview with a consented clinician. The initial tele-assessment session includes interviewing and developmental assessment to mimic real-world use of TAP-Preschool. After the session, the examiner will record the clinical diagnosis issued (ASD, other developmental concerns, or typical development) and complete two diagnostic certainty ratings. All initial TAP-Preschool administrations will be recorded via Zoom, and 50% of administrations (randomly selected) will be co-scored by a blinded examiner, unaware of prior assessment results and diagnostic decision, to evaluate inter-rater reliability. Within 7 days of the remote assessment, families will participate in an in-person diagnostic assessment including common comprehensive measures of ASD, cognitive skills, and adaptive behavior.
Study: NCT06742632

Intervention type: BEHAVIORAL
Intervention: Symptoms checklist-90
Description: The Symptom Checklist-90 (SCL90) is a 90-item questionnaire used to assess psychological problems. The Symptom Checklist-90-Revised (SCL90R) is the revised version of the questionnaire.

Intervention type: BEHAVIORAL
Intervention: Symptoms checklist-90
Description: The Symptom Checklist-90 (SCL90) is a 90-item questionnaire used to assess psychological problems. The Symptom Checklist-90-Revised (SCL90R) is the revised version of the questionnaire.
Study: NCT06741592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDDY Group
Description: The EDDY activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUI Group
Description: The passive ultrasonic activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.
Study: NCT06741579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: The Nalu Peripheral Nerve Stimulator is an FDA-approved, surgically implanted PNS device meant to provide a drug-free pain management approach for patients experiencing chronic neuropathic pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care Regimen
Description: CMM-Only participants will receive conventional medical management for the duration of their time in the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Care Regimen
Description: CMM-Only participants will receive conventional medical management for the duration of their time in the study.
Study: NCT06741462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital health assistant ADELE A0004
Description: The digital health assistant ADELE A0004 (ADELE for short) improves the daily lives of patients with care level and enables them to deal better and more independently with the everyday burdens resulting from the need for care. Participants in the intervention group were provided with ADELE to use during the study period for e.g., tracking of daily reminders, voice-based recording, interpretation and classification of their vital signs and body conditions.
Study: NCT06742021

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
Description: Chest MRI scans outside of the standard treatment protocol
Study: NCT06030752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation
Description: The prepared microbiota suspension was infused into the participates' lower gut.
Study: NCT04584294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPath Web-Based Informational and Decision Support Tool
Description: The MyPath Decision Support Tool includes the following sections and features:~* Questions to capture reproductive goals and orientations towards a potential pregnancy~* Education modules about the menstrual cycle, fertility, and prepregnancy health with the opportunity to flag topics that are relevant and of interest to the patient~* A contraceptive decision module that provides education, elicits patient preferences about different aspects of contraception, and suggests methods most appropriate based on the patient's preferences~* A feature for adding free-text questions that patients may have for their provider~* An email with a summary page that the patient can bring to a visit to guide discussions with primary care providers about reproductive needs
Study: NCT05979116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: MFR in its simplest form targeted restoration of mobility of myofascial and fascial layers from within, and with the surrounding structure. MFR techniques utilized with the cases include different variations of application: 1. Muscle was stroked in a long
Study: NCT05816785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Week 1: loading dose of 400mg/m2; Week 2: 250mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 400 mg orally daily
Study: NCT05655078

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Description: 5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).
Study: NCT06432647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1105
Description: ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.
Study: NCT06413433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Description: Solriamfetol tablets, taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Description: Solriamfetol tablets, taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken once daily
Study: NCT05051930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3721 suspension for inhalation
Description: Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC3721 suspension placebo for inhalation
Description: Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
Study: NCT05866848

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flour capsules as a placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anhydrous caffeine (45mg)
Description: Capsules dosed with 45mg of anhydrous caffeine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anhydrous caffeine (120mg)
Description: Capsules dosed with 120mg of anhydrous caffeine.
Study: NCT05086237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: Text messages will be sent to parents/guardians of children ages 0 to 17 years who missed their well child visits.
Study: NCT05200767

Intervention type: OTHER
Intervention: completing surveys
Description: The level of usual physical activity before the disease ( COVID-19- coronavirus disease 2019) will be analysed based on the IPAQ ( International Physical Activity Questionnaire) results.
Study: NCT04769362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of β-blocker
Description: Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
Study: NCT06050993

Intervention type: OTHER
Intervention: Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.
Description: During the preoperative procedure scheduled at the Paul Brousse hospital, 3 additional blood tubes (total volume 12 ml) will be withdrawn in addition of samplings already done for the patient's standard of care.
Study: NCT05827666

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rice milk alternative beverage
Description: Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rice milk alternative beverage
Description: Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.
Study: NCT05821595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1907
Description: for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1907
Description: for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1907
Description: for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1907
Description: for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1907
Description: for injection
Study: NCT05232526

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mental imagery (MI) and exercise program
Description: Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental imagery (MI) and exercise program
Description: Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mental Imagery and Exercise program
Description: Questionnaires and functional tests are going to be used to evaluate balance, functional status, cognitive ability, depression and quality of life of the sample.
Study: NCT05916248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen tumor vaccine
Description: Neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
Study: NCT05827666

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rice milk alternative beverage
Description: Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.
Study: NCT04261738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Volunteers will be given a standard hyperbaric oxygen treatment (2.4 ATA x 90 minutes)
Study: NCT05591833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SASI
Description: Single-Anastomosis Sleeve ileal (SASI) Bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAS-J
Description: Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
Study: NCT04772235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib~Part B: at the RP2D for all patients in combination with osimertinib.
Study: NCT05393193

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point-of-Care Cepheid Xpert HIV-1
Description: Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.

Intervention type: DRUG
Group type: OTHER
Intervention: DTG/ABC/3TC
Description: Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
Study: NCT05143177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evogliptin
Description: DA-1229 5mg, 1 tab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evogliptin
Description: DA-1229 10 mg, 1 tab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DA-1229 Placebo, 1 tab
Study: NCT05955508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administration by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administration by intravenous (IV) infusion
Study: NCT06177808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wolverine cutting balloon
Description: As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Wolverine cutting balloon for calcium modification.